Cross-species comparison of the metabolism and excretion of zoniporide: Contribution of aldehyde oxidase to interspecies differences

Drug Metabolism and Disposition

Volumn 38, Issue 4, 2010, Pages 641-654

  Dalvie, Deepak ^a   Zhang, Chenghong ^a,b   Chen, Weichao ^a,c   Smolarek, Teresa ^a   Obach, R Scott ^a   Loi, Cho Ming ^a  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

^c ARENA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; CARBOXYLIC ACID; DRUG METABOLITE; GUANIDINE; ZONIPORIDE;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HYDROLYSIS; DRUG METABOLISM; ENZYME KINETICS; EXPERIMENTAL DOG; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SINGLE DRUG DOSE; SPECIES COMPARISON; SPECIES DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; ALDEHYDE OXIDASE; ANIMALS; AREA UNDER CURVE; BIOTRANSFORMATION; BODY BURDEN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; FECES; FEMALE; GUANIDINES; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SUBCELLULAR FRACTIONS; YOUNG ADULT;

CANIS FAMILIARIS; RATTUS;

EID: 77950207218     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030783     Document Type: Article

References (26)

1. Acheampong AA, Chien DS, Lam S, Vekich S, Breau A, Usansky J, Harcourt D, Munk SA, Nguyen H, Garst M, et al. (1996) Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 26:1035-1055.
2. Atrakchi AH (2009) Interpretation and considerations on the safety evaluation of human drug metabolites. Chem Res Toxicol 22:1217-1220.
3. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
4. Davis-Bruno KL and Atrakchi A (2006) A regulatory perspective on issues and approaches in characterizing human metabolites. Chem Res Toxicol 19:1561-1563.
5. Ehlhardt WJ, Woodland JM, Baughman TM, Vandenbranden M, Wrighton SA, Kroin JS, Norman BH, and Maple SR (1998) Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations. Drug Metab Dispos 26:42-51.
6. Food and Drug Administration (2008) Guidance for Industry: Safety Testing of Drug Metabolites. Food and Drug Administration, Rockville, MD.
7. Guzman-Perez A, Wester RT, Allen MC, Brown JA, Buchholz AR, Cook ER, Day WW, Hamanaka ES, Kennedy SP, Knight DR, et al. (2001) Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. Bioorg Med Chem Lett 11:803-807.
8. Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413.
9. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
10. Jordan CG, Rashidi MR, Laljee H, Clarke SE, Brown JE, and Beedham C (1999) Aldehyde oxidase-catalyzed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol 51:411-418.
11. Kaye B, Rance DJ, and Waring L (1985) Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man. Xenobiotica 15:237-242.
12. Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
13. Knight DR, Smith AH, Flynn DM, MacAndrew JT, Ellery SS, Kong JX, Marala RB, Wester RT, Guzman-Perez A, Hill RJ, et al. (2001) A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo. J Pharmacol Exp Ther 297:254-259.
14. Kulanthaivel P, Barbuch RJ, Davidson RS, Yi P, Rener GA, Mattiuz EL, Hadden CE, Goodwin LA, and Ehlhardt WJ (2004) Selective reduction of N-oxides to amines: application to drug metabolism. Drug Metab Dispos 32:966-972.
15. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, and Scatina JA (2002) Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 32:835-847.
16. Lantz RJ, Gillespie TA, Rash TJ, Kuo F, Skinner M, Kuan HY, and Knadler MP, and Knadler MP (2003) Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 31:1142-1150.
17. + exchanger-1. Eur J Pharmacol 451:37-41.
18. Nicoll-Griffith DA, Chauret N, Yergey JA, Trimble LA, Favreau L, Zamboni R, Grossman SJ, Drey J, and Herold E (1993) Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from β-naphthoflavone-treated rodents (P- 4501A1). Drug Metab Dispos 21:861-867.
19. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
20. Obach RS, Huynh P, Allen MC, and Beedham C (2004) Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7-19.
21. Rashidi MR, Smith JA, Clarke SE, and Beedham C (1997) In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 25:805-813.
22. Renwick AB, Ball SE, Tredger JM, Price RJ, Walters DG, Kao J, Scatina JA, and Lake BG (2002) Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica 32:849-862.
23. Schofield PC, Robertson IG, and Paxton JW (2000) Inter-species variation in the metabolism and inhibition of N-[(2′-dimethylamino)ethyl]acridine-4- carboxamide (DACA) by aldehyde oxidase. Biochem Pharmacol 59:161-165.
24. Smith DA and Obach RS (2005) Seeing through the MIST: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab Dispos 33:1409-1417.
25. Smith DA and Obach RS (2006) Metabolites and safety: what are the concerns, and how should we address them? Chem Res Toxicol 19:1570-1579.
26. Tracey WR, Allen MC, Frazier DE, Fossa AA, Johnson CG, Marala RB, Knight DR, and Guzman-Perez A (2003) Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovascular Drug Rev 21:17-32.